Drotrecogin alfa (activated) in adults with septic shock.

By V. Marco Ranieri, B. Thompson, P. Barie, J. Dhainaut, I. Douglas, S. Finfer, B. Gårdlund, J. Marshall, A. Rhodes, A. Artigas and 8 more. New England Journal of Medicine, 2012

1,264 citations recorded by the source corpus.

Subfields: Critical Care and Intensive Care Medicine, Epidemiology, Immunology

View Paper: https://www.semanticscholar.org/paper/9850a504d52419dee6d49cc14167cbd203cb93a9

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Critical Care and Intensive Care Medicine

In Epidemiology

In Immunology

Citations in the corpus

Critical care - where have we been and where are we going? (2013, background): “Repeatedly, new approaches have failed to live up to the promise shown in preclinical or single-center studies: tight glucose control [23,24], moderate-dose steroids in septic shock [25,26], and activated protein C [27,28], to name just a few.”
Sepsis and septic shock. (2018, methodology): “129 Despite promising initial results with regard to the modulation of inflammation and coagulation with drotrecogin alfa, further multicentre RCTs were unable to confirm this benefit 128 and the drug was removed from the market.”
New fundamentals in hemostasis. (2013, background): “A recently completed placebo-controlled trial in patients with severe sepsis and septic shock was prematurely stopped due to the lack of any significant benefit of rhAPC (239).”
Adjunctive Glucocorticoid Therapy in Patients with Septic Shock (2018, methodology): “‡ Scores on the Acute Physiology and Chronic Health Evaluation (APACHE) II are assessed on a scale from 0 to 71, with higher scores indicating a higher risk of death (a score of ≥25 has been used as a cutoff point to identify patients at a higher risk for death).(23-25) § The values for baseline the”
Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis. (2019, neutral): “4) Renal Blood urea nitrogen, median (IQR), mg/dL 24 (15-38) 16 (11-22) 38 (27-55) 23 (15-34) 32 (20-52) Creatinine, median (IQR), mg/dL 1.”
Systemic inflammatory response syndrome criteria in defining severe sepsis. (2015, methodology): “APACHE III was developed in 1991 [5] and was validated and further updated in 1998 [6].”
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016 (2017, methodology): “Recombinant activated protein C, which was originally recommended in the 2004 and 2008 SSC guidelines, was not shown to be effective for adult patients with septic shock by the PROWESS-SHOCK trial, and was withdrawn from the market [345].”